PMID- 27489380
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160804
LR  - 20201001
IS  - 1738-1088 (Print)
IS  - 2093-4327 (Electronic)
IS  - 1738-1088 (Linking)
VI  - 14
IP  - 3
DP  - 2016 Aug 31
TI  - Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of 
      First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial.
PG  - 261-9
LID - 10.9758/cpn.2016.14.3.261 [doi]
AB  - OBJECTIVE: We investigated the efficacy and tolerability of paliperidone 
      extended-release (ER) tablets in patients with first-episode psychosis (n=75). 
      METHODS: This was an 8-week, open-label, multicenter trial. The primary outcome 
      variable was scores on the Positive and Negative Syndrome Scale (PANSS); 
      secondary measures included the Scale for the Assessment of Negative Symptoms 
      (SANS), the Cognitive Assessment Interview (CAI), and the Global Assessment of 
      Functioning (GAF). To assess safety, we measured drug-related adverse events, 
      weight, lipid-related variables, and prolactin and administered the Simpson-Angus 
      Rating Scale (SARS), the Abnormal Involuntary Movement Scale (AIMS), the Barnes 
      Akathisia Scale (BAS), the Arizona Sexual Experiences Scale (ASEX), and the 
      Udvalg for Kliniske Undersogelser side effect rating scale (UKU). RESULTS: The 
      administration of paliperidone ER resulted in significant improvement in the 
      PANSS, SANS, CAI, and GAF scores (p＜0.001) over time. This improvement was 
      evident as early as 1 week. The most frequent adverse events were akathisia, 
      somnolence, anxiety, and sedation, which were well tolerated. Modest increases in 
      weight and lipid profiles were also noted. Prolactin levels were substantially 
      increased at the endpoint in both male and female patients. CONCLUSION: These 
      results indicate that paliperidone ER is effective and is characterized by good 
      tolerability in the treatment of positive and negative symptoms and cognitive 
      functioning in first-episode psychosis.
FAU - Kang, Nam-In
AU  - Kang NI
AD  - Department of Psychiatry, Maeumsarang Hospital, Wanju, Korea.
FAU - Koo, Bon-Hoon
AU  - Koo BH
AD  - Department of Psychiatry, Yeungnam University, Gyeongsan, Korea.
FAU - Kim, Sung-Wan
AU  - Kim SW
AD  - Department of Psychiatry, Chonnam National University Medical School, Gwangju, 
      Korea.
FAU - Kim, Jong-Hoon
AU  - Kim JH
AD  - Department of Psychiatry, Gachon University Gil Medical Center, Gachon University 
      School of Medicine, Incheon, Korea.
FAU - Nam, Beomwoo
AU  - Nam B
AD  - Department of Psychiatry, Konkuk University School of Medicine, Cheongju, Korea.
FAU - Lee, Bong-Ju
AU  - Lee BJ
AD  - Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University 
      College of Medicine, Busan, Korea.
FAU - Lee, Sang-Hyuk
AU  - Lee SH
AD  - Department of Psychiatry, CHA Bundang Medical Center, CHA University, Seongnam, 
      Korea.
FAU - Lee, Seung Jae
AU  - Lee SJ
AD  - Department of Psychiatry, Kyoungpook National University School of Medicine, 
      Daegu, Korea.
FAU - Lee, Seung-Hwan
AU  - Lee SH
AD  - Department of Psychiatry, Inje University Ilsan Paik Hospital, Goyang, Korea.
FAU - Jung, Myung Hun
AU  - Jung MH
AD  - Department of Psychiatry, Hallym University Sacred Heart Hospital, Anyang, Korea.
FAU - Hahn, Sang Woo
AU  - Hahn SW
AD  - Department of Psychiatry, Soonchunhyang University Seoul Hospital, Soonchunhyang 
      University College of Medicine, Seoul, Korea.
FAU - Chung, Young-Chul
AU  - Chung YC
AD  - Department of Psychiatry, Chonbuk National University Hospital, Jeonju, Korea.
AD  - Research Institute of Clinical Medicine of Chonbuk National University-Biomedical 
      Research Institute of Chonbuk National University Hospital, Jeonju, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Clin Psychopharmacol Neurosci
JT  - Clinical psychopharmacology and neuroscience : the official scientific journal of 
      the Korean College of Neuropsychopharmacology
JID - 101207332
PMC - PMC4977821
OTO - NOTNLM
OT  - Efficacy
OT  - First-episode psychosis
OT  - Paliperidone extended-release
OT  - Tolerability
EDAT- 2016/08/05 06:00
MHDA- 2016/08/05 06:01
PMCR- 2016/08/01
CRDT- 2016/08/05 06:00
PHST- 2015/11/26 00:00 [received]
PHST- 2016/01/03 00:00 [revised]
PHST- 2016/01/04 00:00 [accepted]
PHST- 2016/08/05 06:00 [entrez]
PHST- 2016/08/05 06:00 [pubmed]
PHST- 2016/08/05 06:01 [medline]
PHST- 2016/08/01 00:00 [pmc-release]
AID - cpn.2016.14.3.261 [pii]
AID - cpn-14-261 [pii]
AID - 10.9758/cpn.2016.14.3.261 [doi]
PST - ppublish
SO  - Clin Psychopharmacol Neurosci. 2016 Aug 31;14(3):261-9. doi: 
      10.9758/cpn.2016.14.3.261.